Market value of drugmaker climbs by £6.5bn as trial shows ‘significant weight loss’ for pill version of Wegovy
The value of the drugmaker Novo Nordisk has shot up by more than £6.5bn after research showed its new anti-obesity pill resulted in almost as much weight loss as its Wegovy jab, as it races against its US rival Eli Lilly to get a tablet treatment to market.
Stock in the Danish company climbed by more than 4.5% on Thursday morning on hopes it could claw back market share lost to Eli Lilly and cheaper generic versions of GLP-1 drugs. The shares have fallen by nearly 60% in the past year as sales slowed.
Continue reading...
